Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.

Treatment resistance, as indicated by the presence of high levels of minimal residual disease (MRD) after induction therapy and induction consolidation, is associated with a poor prognosis in childhood acute lymphoblastic leukemia (ALL). We hypothesized that treatment resistance is an intrinsic feature of ALL cells reflected in the gene expression pattern and that resistance to chemotherapy can be predicted before treatment. To test these hypotheses, gene expression signatures of ALL samples with high MRD load were compared with those of samples without measurable MRD during treatment. We identified 54 genes that clearly distinguished resistant from sensitive ALL samples. Genes with low expression in resistant samples were predominantly associated with cell-cycle progression and apoptosis, suggesting that impaired cell proliferation and apoptosis are involved in treatment resistance. Prediction analysis using randomly selected samples as a training set and the remaining samples as a test set revealed an accuracy of 84%. We conclude that resistance to chemotherapy seems at least in part to be an intrinsic feature of ALL cells. Because treatment response could be predicted with high accuracy, gene expression profiling could become a clinically relevant tool for treatment stratification in the early course of childhood ALL.

[1]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Harbott,et al.  Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. , 2004, Blood.

[3]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Aniko Szabo,et al.  Identification of gene expression profiles that segregate patients with childhood leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M J T Reinders,et al.  DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers , 2003, Leukemia.

[6]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[7]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. , 2000, Leukemia.

[8]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[9]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[10]  M J T Reinders,et al.  DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers , 2004, Leukemia.

[11]  A. Borkhardt,et al.  Multiplex PCR – a rapid screening method for detection of gene rearrangements in childhood acute lymphoblastic leukemia , 1999, Annals of Hematology.

[12]  D. Botstein,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[13]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Mustafa Ozen,et al.  Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. , 2003, Cancer research.

[15]  S. Knudsen,et al.  Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarrays , 2004, Leukemia.

[16]  H. Youssoufian,et al.  MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. , 1997, The Journal of clinical investigation.

[17]  R. Gentleman,et al.  Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. , 2004, Blood.

[18]  M. Schrappe,et al.  PROGNOSTIC VALUE OF MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA. A PROSPECTIVE STUDY OF THE INTERNATIONL BFM STUDY GROUP. , 1998 .

[19]  J. Downing,et al.  Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. , 2003, Blood.

[20]  J. Downing,et al.  Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells , 2003, Nature Genetics.

[21]  H. Döhner,et al.  Evidence for distinct pathomechanisms in B-cell chronic lymphocytic leukemia and mantle cell lymphoma by quantitative expression analysis of cell cycle and apoptosis-associated genes. , 2002, Blood.

[22]  D. Hogg,et al.  Cell cycle dependent regulation of the protein kinase TTK. , 1994, Oncogene.

[23]  E. Lander,et al.  MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia , 2002, Nature Genetics.

[24]  Misao Ohki,et al.  Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. , 2003, Cancer research.

[25]  J. Harbott,et al.  Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995 , 2000, Leukemia.

[26]  J. Downing,et al.  Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. , 2002, Cancer cell.

[27]  Martyn T. Smith,et al.  Real‐time reverse transcription polymerase chain reaction detection and quantification of t(1;19) (E2A–PBX1) fusion genes associated with leukaemia , 2001, British Journal of Haematology.

[28]  M. Winey,et al.  The yeast protein kinase Mps1p is required for assembly of the integral spindle pole body component Spc42p , 2002, The Journal of cell biology.

[29]  W. Hop,et al.  Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. , 2002, Blood.

[30]  A Orfao,et al.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). , 1995, Leukemia.

[31]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.